Meacham R H, Ruelius H W, Kick C J, Peters J R, Kocmund S M, Sisenwine S F, Wendt R L
J Pharmacol Exp Ther. 1980 Sep;214(3):594-8.
The antihypertensive agent guanabenz (E-2,6-dichlorobenzylidene aminoguanidine acetate. Wy-8678) was administered i.v. in single doses of 10, 32 and 100 microgram/kg to groups of spontaneously hypertensive rats. Mean arterial blood pressure and heart rate were monitored continuously. Animals were decapitated at predetermined time intervals and concentrations of the drug in whole brain and plasma were measured by a specific gas chromatographic method. After an initial transient increase in blood pressure, significant dose-dependent maximal decreases in pressure of 15 +/- 8, 46 +/- 20 and 59 +/- 15 mm Hg (mean +/- S.D.) were observed 15 to 30 min after injection of the above respective doses. At the line of the maximal decreases in pressure (T delta max), concentrations of guanabenz in brain were 10 +/- 2, 29 +/- 8 and 89 +/- 21 ng/g and correlated significantly with dose and the magnitude of blood pressure change. The correlation between concentration in brain and change in blood pressure was also significant at subsequent sacrifice times. Concentrations of guanabenz in plasma were below the limit of detection after the 10 microgram/kg dose. At the two higher doses, concentrations in plasma were dose related but did not correlate with decreases in blood pressure. The correlation between concentration in brain and change in blood pressure is in agreement with the predominantly central mechanism of action of guanabenz.
抗高血压药胍那苄(E-2,6-二氯亚苄基氨基胍乙酸盐,Wy-8678)以10、32和100微克/千克的单剂量静脉注射给几组自发性高血压大鼠。连续监测平均动脉血压和心率。在预定的时间间隔将动物断头,并通过特定的气相色谱法测量全脑和血浆中的药物浓度。在血压最初短暂升高后,注射上述相应剂量后15至30分钟观察到显著的剂量依赖性最大血压下降,分别为15±8、46±20和59±15毫米汞柱(平均值±标准差)。在最大血压下降时(Tδmax),胍那苄在脑中的浓度分别为10±2、29±8和89±21纳克/克,与剂量和血压变化幅度显著相关。在随后的处死时间,脑中浓度与血压变化之间的相关性也很显著。10微克/千克剂量后,血浆中胍那苄的浓度低于检测限。在两个较高剂量时,血浆中的浓度与剂量相关,但与血压下降无关。脑中浓度与血压变化之间的相关性与胍那苄主要的中枢作用机制一致。